Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD pediatric patiromer study in chronic kidney disease with hyperkalemia
2016-002785-31Phase 2Completed
- Sponsor
- Vifor Pharma
- Start
- Dec 2016
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of patiromer in hyperkalemia, sponsored by Vifor Pharma. Primary endpoint: Change in serum potassium from baseline to Day 14. Started Dec 2016; status: completed.
02
Drugs
patiromer
03
Conditions
hyperkalemia
Beyond the preview
Go deeper on 2016-002785-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002785-31.